

Abstract SIOPEN 2015 : High frequency of subclonal *ALK* mutations in high risk neuroblastoma patients. A SIOPEN study.

Angela Bellini¹, Virginie Bernard¹, Eve Lapouble¹, Nathalie Clement¹, Gaelle Pierron¹, Inge M. Ambros², Katleen de Preter³, Nadine Van Roy³, Ales Vicha⁴, Valérie Combaret⁵, David Betts⁶, Marta Jeison⁷, Smadar Avigad⁷, Martina Morini⁸, Luigi Varesio⁸, Barbara Marques⁹, Annick Muhlethaler¹⁰, Rosa Noguera¹¹, Ana Berbegall¹¹, Jaime Font de Mora¹², Peter F. Ambros², Ruth Ladenstein¹³, Dominique Valteau-Couanet¹⁴, Jean Michon¹, Olivier Delattre¹, Nick Bown¹⁵, Deborah Tweddle¹⁵, Gudrun Schleiermacher¹

¹Institut Curie, Paris, France

²Children's Cancer Research Institute, Vienna, Austria

³Ghent University, Ghent, Belgium

⁴Charles University, Prague, Czech Republic

⁵Centre Léon Berard, Lyon, France

⁶Our Lady's Children's Hospital, Dublin Ireland

⁷Schneider Children's Medical Center of Israel, , Tel Aviv University, Israel

⁸Istituto G. Gaslini, Genoa, Italy

⁹Centro de Genética Humana, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisboa, Portugal

¹⁰Institut Universitaire de Pathologie, Lausanne , Switzerland

¹¹University of Valencia, Valencia, Spain

¹²Hospital Universitari i Politècnic La Fe, , Valencia, Spain

¹³St Anna Kinderspital, Vienna, Austria

¹⁴Gustave Roussy, Villejuif, France

¹⁵Northern Institute for Cancer Research Medical School, Newcastle, UK

Introduction:

In neuroblastoma (NB), activating *ALK* receptor tyrosine kinase point mutations are detected in 8–10% at diagnosis using conventional sequencing. To determine the potential occurrence and the prognostic impact of *ALK* mutations in a series of high risk NB patients we studied *ALK* variation frequencies using targeted deep sequencing in samples of patients enrolled in the SIOPEN HR-NBL01 study.

Methods:

To date, a series of 326 diagnostic high risk NB samples enrolled in the HRNBL trial has been analyzed, focusing on the exons 23, 24 and 25 containing the F1174, F1245 and R1275 hotspots respectively. DNA was amplified via a two-step PCR approach, the second step consisting of addition of sample-specific barcodes for targeted resequencing in a single experiment. Amplicon sequencing (Illumina HiSeq2500) achieved an extremely high depth over the relevant hotspot (80,000X). The background base variability (error rate) in 32 control samples was 0.017%±/±0.010 at the studied position. Given the mean coverage and error rate, a base frequency >0.06% is significantly different from background noise (Fisher's exact test).

Results:

At the F1174 hotspot, mutations were observed in 21/326 samples. For 11 cases, these mutations, observed with mutated allele fractions of >20%, occurred at a clonal

level, and in 10 additional cases they occurred at a sub-clonal level (range of mutated allele fractions: 0.207% - 4.195%). At the R1275 hotspot, mutations were observed in 26/326 samples, 12 at a clonal and 14 at a sub-clonal level. All clonal mutations were validated by Sanger sequencing. In one case, 2 sub-clonal *ALK* mutations (2.997% and 8.943%) were observed at the same position at the hotspot R1275 with another mutation observed at the hotspot F1174. Validation of all mutations observed at a sub-clonal level and analysis of other samples from collaborating groups is currently ongoing. Correlation between these findings and clinical and biological parameters will be established.

Discussion:

Our ongoing study documents a high frequency of clonal (7%) and sub-clonal *ALK* mutations (7.9%) in high risk NB patients. These findings are of utmost clinical importance given the potential role of *ALK* mutations in clonal evolution and relapse.